Medicinova, Inc.
MNOV Real Time Price USDRecent trades of MNOV by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by MNOV's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Methods of minimizing cancer metastasis Jul. 23, 2024
-
Patent Title: Methods of preventing cancer metastasis Jun. 11, 2024
-
Patent Title: Treatment of progressive neurodegenerative disease with ibudilast Apr. 02, 2024
-
Patent Title: Methods of treating chemical gas exposure Mar. 12, 2024
-
Patent Title: Ibudilast oral formulations and methods of using same Jan. 09, 2024
-
Patent Title: Methods and dosing regimens using ibudilast and a second agent for cancer therapy Sep. 20, 2022
-
Patent Title: Combination of ibudilast and riluzole and methods of using same Mar. 22, 2022
-
Patent Title: Methods of treating ophthalmic disease/disorder or injury with ibudilast Oct. 26, 2021
-
Patent Title: Treatment of progressive neurodegenerative disease with ibudilast Aug. 10, 2021
-
Patent Title: Combination of ibudilast and interferon-beta and methods of using same Mar. 16, 2021
-
Patent Title: Methods and dosing regimens using ibudilast and a second agent for cancer therapy Aug. 18, 2020
-
Patent Title: Methods of treating glioblastoma multiforme using ibudilast Aug. 27, 2019
-
Patent Title: Combination of ibudilast and riluzole and methods of using same Apr. 16, 2019
-
Patent Title: Method of inhibiting or treating fibrosis Nov. 22, 2016
-
Patent Title: Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels Jun. 07, 2016
-
Patent Title: Method of treating advanced non-alcoholic steatohepatitis May. 24, 2016
-
Patent Title: Treatment of amyotrophic lateral sclerosis (als) with ibudilast Apr. 19, 2016
-
Patent Title: Treatment of progressive neurodegenerative disease with ibudilast Aug. 25, 2015
-
Patent Title: Method of treating liver disorders Feb. 24, 2015
-
Patent Title: Method of treating non-alcoholic fatty liver disease and steatohepatitis Sep. 16, 2014
-
Patent Title: Denibulin di-hydrochloride Jan. 21, 2014
-
Patent Title: Methods and compositions for the treatment of irritable bowel syndrome Aug. 27, 2013
-
Patent Title: Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom Apr. 16, 2013
-
Patent Title: Treatment of progressive neurodegenerative disease with ibudilast Dec. 25, 2012
-
Patent Title: Treatment of progressive neurodegenerative disease with ibudilast Mar. 20, 2012
-
Patent Title: Enantiomeric compositions of 2-amino-1-(2-isopropylpyrazolo[1,5-α]pyridin-3-yl)propan-1-one and related methods Feb. 21, 2012
-
Patent Title: Phenoxyalkylcarboxylic acid derivatives in the treatment of irritable bowel syndrome Sep. 27, 2011
-
Patent Title: Phenoxyalkycarboxylic acid derivatives in the treatment of ulcerative colitis Aug. 31, 2010
-
Patent Title: Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use Jun. 01, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of MNOV in WallStreetBets Daily Discussion
Recent insights relating to MNOV
Recent picks made for MNOV stock on CNBC
ETFs with the largest estimated holdings in MNOV
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view MNOV Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.